Patient-reported outcomes. Mean change from baseline and 95% CIs of EORTC QLQ-MY20 scores in DS subscale (A) and side effects of treatment subscale (B) over time with modakafusp alfa 120 mg or 240 mg q4w. CIs were truncated if outside of (−100, 100) and suppressed if there were >5 patients in either treatment arm. Lines at y = 10 and y = −10 were plotted to aid interpretation of subscale trends based on minimally important difference thresholds.¹⁴ EOT, end of treatment; QoL, quality of life.